AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01943630
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Vehicle once a day (overnight)
Trial: NCT03591705
Drug: TACE-HAIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
Trial: NCT03591705
Drug: HAIC
RxNorm normalized name: Hepatic Arterial Infusion Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
Trial: NCT02940886
Drug: Iron isomaltoside/ferric derisomaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.
Trial: NCT01025713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Placebo
Trial: NCT03073603
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
Trial: NCT01181934
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo - three times daily during each treatment period
Trial: NCT01205243
Drug: ZIAGEN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Trial: NCT02473952
Drug: IGIV-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
Trial: NCT02473952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02312739
Drug: Standard Oral pain medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
Trial: NCT02312739
Drug: Intramuscular Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
Trial: NCT02312739
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
Trial: NCT04711265
Drug: Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection with 3 doses of QHPV
Trial: NCT00861939
Drug: WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04434404
Drug: L-Carnitine 500Mg Oral Tablet
RxNorm normalized name: L-Carnitine 500mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months.
Trial: NCT03903029
Drug: Low-dose (10mg) rosuvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
Trial: NCT03701555
Drug: PvP001 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PvP001 100 mg
Trial: NCT03701555
Drug: PvP001 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PvP001 300 mg
Trial: NCT03701555
Drug: PvP001 900 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PvP001 900 mg
Trial: NCT03701555
Drug: PvP001 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PvP001 600 mg
Trial: NCT03701555
Drug: PvP003 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet orally.
Trial: NCT03701555
Drug: PvP003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PvP003 tablet orally.
Trial: NCT03701555
Drug: PvP003 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PvP003 150 mg
Trial: NCT02185352
Drug: BEEP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
Trial: NCT00646802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
Trial: NCT03051932
Drug: Ofiramev® (IV Acetaminophen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post -op pain medication
Trial: NCT03051932
Drug: Placebo IV administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post -op pain
Trial: NCT03351998
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo pill.
Trial: NCT06445465
Drug: [18F]MNI-1216
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
Trial: NCT01652092
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 50 mg/kg IV on days -9 through -6
Trial: NCT01296568
Drug: LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT00642278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
Trial: NCT00569920
Drug: natriumchloride 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
Trial: NCT01858662
Drug: 5-Fluorouracile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
Trial: NCT01858662
Drug: leucovorin L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
Trial: NCT03679481
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
Trial: NCT03531229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Lu AF76432 oral solution
Trial: NCT04018170
Drug: Study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
Trial: NCT04018170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
Trial: NCT00634543
Drug: Tramadol hydrochloride/ Acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
Trial: NCT00685178
Drug: placebo + NonCR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
Trial: NCT00916604
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three increasing dose-steps with oral suspension, 8 days treatment
Trial: NCT00916604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension, 8 days treatment
Trial: NCT04524975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT00538603
Drug: pegylated liposomal Doxorubicin (CAELYX) & Carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT02760602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01202773
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Subcutaneously (SC)
Trial: NCT01202773
Drug: Placebo Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01202773
Drug: Placebo Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03795298
Drug: Market-approved OAC
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
Trial: NCT03159754
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
Trial: NCT00230581
Drug: DDP225
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00950352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
Trial: NCT00978575
Drug: ferricarboxymaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of maximum 1000 mg ferricarboxymaltose intravenous
Trial: NCT00978575
Drug: Ferrosulfate
RxNorm normalized name: isostearyl ethylimidazolinium ethosulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg daily for 12 weeks
Trial: NCT00978575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg isotonic sodium and 2 placebo tablets daily
Trial: NCT01454089
Drug: OGX-427 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
Trial: NCT01454089
Drug: OGX-427 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
Trial: NCT01454089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
Trial: NCT02979223
Drug: sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group
Trial: NCT00707954
Drug: Placebo of TA-7284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
Trial: NCT03264638
Drug: Dingkundan & Diane-35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
Trial: NCT04356105
Drug: Microflare protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCP, GnRH agonist, Recombinant FSH
Trial: NCT00893594
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
Trial: NCT00719173
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00117338
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pbo for a study approximately 120 minutes in duration
Trial: NCT00680407
Drug: Silymarin 700 mg
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg dose (5 pills, three times daily) for 48-50 week treatment period
Trial: NCT00680407
Drug: Silymarin 420 mg
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 mg dose (5 pills, three times daily) for 48-50 week treatment period
Trial: NCT02084953
Drug: Placebo matching BMS-791325
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02266537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003530
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT04592835
Drug: DWRX2003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites
Trial: NCT00647842
Drug: Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT02467595
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
Trial: NCT02576912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo dose given sublingually.
Trial: NCT02576912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose given intravenously.
Trial: NCT00193674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00790296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT00349791
Drug: Testosterone Transdermal System
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone (300 mcg/day) patch replaced twice a week for two years
Trial: NCT00349791
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch replaced twice a week for two years
Trial: NCT00379730
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04263922
Drug: Huaiqihuang granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
Trial: NCT02881619
Drug: Etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
Trial: NCT02881619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive a single-dose of placebo one hour before the bleaching procedure.
Trial: NCT03704818
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment taken daily for 4-weeks.
Trial: NCT00353275
Drug: Strict Glycemic control
RxNorm normalized name: Euphrasia stricta extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose target range is 80-110 mg/dL.
Trial: NCT04135261
Drug: HBM4003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration
Trial: NCT01299597
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
Trial: NCT03241173
Drug: INCAGN01949
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
Trial: NCT02963077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03926182
Drug: AST2818 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
Trial: NCT03926182
Drug: AST2818 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
Trial: NCT04018027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo administered twice daily
Trial: NCT01245894
Drug: Low-dose Rosuvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5mg/day for one year
Trial: NCT01245894
Drug: High-dose Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40mg/day for one year
Trial: NCT00894530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
Trial: NCT03633643
Drug: oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital.
Trial: NCT03633643
Drug: oral applications of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
Trial: NCT00198237
Drug: docetaxel & capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01177150
Drug: JNJ-28431754/ Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
Trial: NCT00929578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of placebo
Trial: NCT04390698
Drug: opioid free anesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
Trial: NCT00081289
Drug: Capecitabine 1200 mg/m^2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/m\^2 q12 hours(1200 mg/m\^2/day) orally 5 days per week during radiotherapy.
Trial: NCT00081289
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.~5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles.
Trial: NCT01019590
Drug: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
RxNorm normalized name: hydrochlorothiazide / olmesartan medoxomil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01019590
Drug: Benicar HCT ® Tablets 40 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no